 |
Selection of Diseases in IVR Portfolio
::
Disease by type
::
Diseases alphabetically
::
Criteria for Selection
Facilitator or Developer ?
IVR is either a developer or a facilitator of research and product development, depending on which is considered to have the biggest impact.
IVR as a developer
IVR acts as a “developer” when a potential candidate vaccine lacks R&D investment and leadership, and where an active role of IVR in product development will benefit the vaccine pipeline for the disease in question. In such cases, IVR will dedicate human and financial resources to specific projects, and combine its own strengths with those of other “developers” by directly supporting certain associated research and management tasks, and/or by forging collaborations and co-sponsorship relationships. IVR is a developer for:
- Measles
- Meningitis A, C, W135
- Rabies
IVR as a facilitator
IVR fulfils a “Facilitator” role when many funding agencies and product development programmes or support structures are already active in the vaccine R&D pipeline. In this situation, IVR impacts on the associated environment rather than participating directly in building the individual components of the R&D pipeline itself. As a Facilitator, IVR does not sponsor the development of specific vaccine candidates, but supports global research and product development as an independent, objective, process consultant and strategic or technical adviser. In terms of financial involvement, IVR can provide seed funds, bridging support, or resources to developing countries for research that is needed for future vaccine introduction. IVR is a facilitator for:
- HIV/AIDS
- Cervical Cancer (Human Papilomavirus)
- Dengue
- Enterotoxigenic E. coli
- Influenza
- Japanese encephalitis
- Leishmaniasis
- Malaria
- Rotavirus diarrhoea
- Shigellosis
- Streptococcus A
- Streptococcus pneumoniae (Acute Respiratory Infections)
- Tuberculosis
|
|
